WJA
IMDX

Williams Jones & Associates’s Insight Molecular Diagnostics IMDX Stock Holding History

Williams Jones & Associates’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$37K Sell
750
-1
-0.1% -$83 ﹤0.01% 390
2019
Q1 		$59K Hold
751
– – ﹤0.01% 399
2018
Q4 		$21K Hold
751
– – ﹤0.01% 391
2018
Q3 		$38K Sell
751
-13
-2% -$671 ﹤0.01% 440
2018
Q2 		$39K Buy
+764
New +$37.6K ﹤0.01% 437

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Williams Jones & Associates's IMDX Position: Q2 2019 in Review

Williams Jones & Associates reduced its Insight Molecular Diagnostics (IMDX) stake by 0.13% in Q2 2019, selling an estimated $83 and leaving 750 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #390.

Williams Jones & Associates first reported a position in IMDX in Q2 2018 and has held it in 5 quarters since. The position peaked at $59K in Q1 2019. 54 funds tracked by Wall St. Rank hold IMDX as of Q2 2019.

  • Williams Jones & Associates held 750 shares of Insight Molecular Diagnostics worth $37K as of Q2 2019.
  • Williams Jones & Associates sold 1 Insight Molecular Diagnostics share in Q2 2019, an estimated $83.
  • Insight Molecular Diagnostics made up ﹤0.01% of Williams Jones & Associates's portfolio in Q2 2019, its #390 holding.
  • Williams Jones & Associates first reported a position in Insight Molecular Diagnostics in Q2 2018 and has held it in 5 quarters since.
  • Williams Jones & Associates's Insight Molecular Diagnostics position peaked at $59K in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.